Key Highlights Brian Armstrong’s biotech venture NewLimit secured $435 million in fresh funding, elevating its valuation to $3.1 billion The company’s worth has surged more than threefold fro
The Coinbase chief executive made his billions through cryptocurrency. Now Brian Armstrong is channeling massive capital into a radically different mission: restoring youth to aging human cells.
Coinbase Co-Founder Brian Armstrong;s Longevity Startup NewLimit Raises $435M Series C
NewLimit, a longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, announced a $435 million Series C round led by Founders Fund. New investors including Thrive Capital,… pic.twitter.com/nMPiPF8lHZ
— Wu Blockchain (@WuBlockchain) June 3, 2026
NewLimit, the Bay Area-based biotechnology firm Armstrong helped launch, has successfully completed a $435 million financing round. This latest capital injection brings the venture’s post-money valuation to $3.1 billion — representing more than a tripling of its worth from the Series B valuation recorded under a year ago.
Armstrong established NewLimit in 2022 with co-founders Blake Byers and Jacob Kimmel. Kimmel brings experience from Alphabet’s Calico, a dedicated longevity research laboratory.
The scientific foundation of NewLimit rests on epigenetic reprogramming. Rather than losing their genetic code with age, human cells gradually lose their capacity to interpret that code as they once did during youth. NewLimit’s therapeutic approach employs molecular instruments known as transcription factors to restore gene expression in aging cells to patterns resembling those of younger cells.
The company’s delivery system relies on lipid nanoparticles — the identical foundational technology that powers mRNA vaccines developed for COVID-19.
No NewLimit therapies have been administered to human subjects to date. While the company has completed preclinical research, including screening with human cells and experiments involving animal models, clinical trials with people remain on the horizon.
The company intends to submit its inaugural clinical trial application in 2027, with alcohol-induced liver disease as the initial target condition. NewLimit’s primary research emphasis spans liver function, immune system performance, and vascular health.
The entire $3.1 billion valuation rests on preclinical findings alone.
NewLimit’s approach falls within what scientists term partial epigenetic reprogramming. Rather than fully reverting cells to a stem-cell state — which could trigger cancer risks — the company aims for a controlled, limited restoration of cellular youth.
The financing timeline demonstrates rapidly accelerating investor enthusiasm. NewLimit’s $130 million Series B round in May 2025, spearheaded by Kleiner Perkins, has been eclipsed by this new round exceeding three times that figure in one closing.
The straightforward answer: there isn’t one. NewLimit operates without any cryptocurrency token, blockchain infrastructure, or decentralized technology component. Armstrong’s leadership position at Coinbase remains entirely distinct from his involvement with NewLimit.
For those tracking Armstrong due to his role at one of the planet’s premier cryptocurrency platforms, this represents a standard biotechnology venture capital opportunity.
Raising $435 million ahead of any human testing signals robust institutional confidence. Kleiner Perkins, having led the previous funding round, continues its participation.
NewLimit now stands among an expanding roster of longevity-focused startups receiving support from technology industry billionaires. The next critical benchmark arrives when the firm files its clinical trial documentation, anticipated in 2027.
The post Brian Armstrong’s Anti-Aging Venture NewLimit Secures $435M in Massive Funding Round appeared first on Blockonomi.
